GB2608978A - Canine parvovirus nanobody CPV-VHH-D4 and application thereof - Google Patents

Canine parvovirus nanobody CPV-VHH-D4 and application thereof Download PDF

Info

Publication number
GB2608978A
GB2608978A GB2216575.7A GB202216575A GB2608978A GB 2608978 A GB2608978 A GB 2608978A GB 202216575 A GB202216575 A GB 202216575A GB 2608978 A GB2608978 A GB 2608978A
Authority
GB
United Kingdom
Prior art keywords
cpv
insdseq
vhh
insdqualifier
nanobody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB2216575.7A
Other languages
English (en)
Other versions
GB202216575D0 (en
Inventor
Jia Hong
Zhu Hongfei
Yuan Weifeng
Feng Qianqian
Wang Zhaoyang
Huang Ying
Zhai Wenzhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Animal Science of CAAS
Original Assignee
Institute of Animal Science of CAAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Animal Science of CAAS filed Critical Institute of Animal Science of CAAS
Publication of GB202216575D0 publication Critical patent/GB202216575D0/en
Publication of GB2608978A publication Critical patent/GB2608978A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GB2216575.7A 2021-11-12 2022-11-07 Canine parvovirus nanobody CPV-VHH-D4 and application thereof Pending GB2608978A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111337112.2A CN113861286B (zh) 2021-11-12 2021-11-12 犬细小病毒纳米抗体cpv-vhh-d4及其应用

Publications (2)

Publication Number Publication Date
GB202216575D0 GB202216575D0 (en) 2022-12-21
GB2608978A true GB2608978A (en) 2023-01-18

Family

ID=78984435

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2216575.7A Pending GB2608978A (en) 2021-11-12 2022-11-07 Canine parvovirus nanobody CPV-VHH-D4 and application thereof

Country Status (2)

Country Link
CN (1) CN113861286B (zh)
GB (1) GB2608978A (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103665152A (zh) * 2013-12-02 2014-03-26 山西农业大学 犬细小病毒单域抗体及其制备方法和应用
WO2020099922A1 (en) * 2018-11-13 2020-05-22 Novobind Livestock Therapeutics, Inc. Antibodies against disease causing agents of canines and felines and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2223029A1 (en) * 1997-02-12 1998-08-12 Akzo Nobel Nv Canine parvovirus dna vaccines
CN109369803B (zh) * 2018-09-07 2021-05-04 深圳市国创纳米抗体技术有限公司 一种抗狂犬病毒g蛋白的纳米抗体及其应用
CN109212230B (zh) * 2018-09-12 2021-11-30 东北农业大学 用于检测犬细小病毒结构蛋白vp2抗体的致敏聚苯乙烯纳米微球及其制备方法和应用
CN109627331B (zh) * 2019-01-22 2022-03-29 长春西诺生物科技有限公司 一种抗犬细小病毒抗体的重链、轻链可变区及基因工程抗体
CN113336843B (zh) * 2020-03-02 2022-04-05 北京市农林科学院 一种用于抗犬细小病毒病的单链抗体及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103665152A (zh) * 2013-12-02 2014-03-26 山西农业大学 犬细小病毒单域抗体及其制备方法和应用
WO2020099922A1 (en) * 2018-11-13 2020-05-22 Novobind Livestock Therapeutics, Inc. Antibodies against disease causing agents of canines and felines and uses thereof

Also Published As

Publication number Publication date
GB202216575D0 (en) 2022-12-21
CN113861286B (zh) 2022-10-25
CN113861286A (zh) 2021-12-31

Similar Documents

Publication Publication Date Title
CN105669838B (zh) 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体
CN111848786B (zh) 一种单克隆抗体、其制备方法及用途
CN111057145B (zh) 猪繁殖与呼吸综合征病毒Nsp2蛋白纳米抗体及其应用
CN114874995B (zh) 猪瘟病毒2型Erns蛋白的单克隆抗体杂交瘤细胞株及应用
CN110551212A (zh) 抗gii.4型诺如病毒衣壳蛋白vp1和病毒样颗粒vlp单克隆抗体的制备方法和应用
CN113150124B (zh) 一种基于非洲猪瘟病毒p72基因的双抗体夹心ELISA及其应用
CN108892723B (zh) 用于检测猪流行性腹泻病毒的单域重链抗体、制备方法及应用
CN110845624B (zh) 一种sumo-cp融合蛋白及其制备方法以及其多克隆抗体的制备方法
US20240067706A1 (en) Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof
US11767356B1 (en) Canine parvovirus nanobody CPV-VHH-E3 and application thereof
KR20220009960A (ko) 재조합 고전적 돼지 열병 바이러스
CN113563461B (zh) 一种基于非洲猪瘟病毒CD2v蛋白的竞争性单克隆抗体、试剂盒及其应用
CN117964746A (zh) 一种a型口蹄疫病毒中和抗体hy2及其制备方法与应用
CN117903300A (zh) 一种a型口蹄疫病毒中和抗体hy1及其制备方法与应用
KR20230123463A (ko) 재조합 고전적 돼지 열 바이러스 e2 단백질
CN110257405B (zh) 牛支原体乙醇脱氢酶基因及其编码蛋白与应用
CN113150079A (zh) 一种真核表达的非洲猪瘟病毒p72抗原及其应用
GB2608978A (en) Canine parvovirus nanobody CPV-VHH-D4 and application thereof
CN113061167B (zh) 兔出血症病毒重组抗原及其应用
CN115304678A (zh) 基于dc细胞的双功能纳米抗体及其构建方法和应用
CN109553680B (zh) 一种单克隆抗体ZKns4B8及其应用
Zhou et al. High throughput screening of scFv antibodies against viral hemorrhagic septicaemia virus by flow cytometry
CN113861287B (zh) 犬细小病毒纳米抗体cpv-vhh-h1及其应用
CN114085287B (zh) 犬细小病毒纳米抗体cpv-vhh-f5及其应用
JP2002020399A (ja) ノルウォークウイルス（ｎｖ）を認識するモノクローナル抗体